Trastuzumab
- Generic Name
- Trastuzumab
- Brand Names
- Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ontruzant, Perjeta-Herceptin, Phesgo, Trazimera, Herwenda, Ogivri, Zercepac, Tuznue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 180288-69-1
- Unique Ingredient Identifier
- P188ANX8CK
- Background
Produced in CHO cell cultures, trastuzumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein (HER2). It is used as a treatment of human epidermal growth factor receptor (HER)-2+ metastatic bre...
- Indication
For the adjuvant treatment of HER2-overexpressing breast cancer, trastuzumab is indicated in several clinical settings: as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a treatment regimen with docetaxel and carboplatin; or as monotherapy following multi-modality anthracycline-based th...
- Associated Conditions
- Breast Cancer, Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Adenocarcinoma of the Stomach, Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage I Breast Cancer
- Associated Therapies
- -
Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 96
- Registration Number
- NCT00193076
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2014-03-12
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193063
A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-09-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 66
- Registration Number
- NCT00191373
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States
🇺🇸For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00169104
TBP Study With Capecitabine Plus Minus Trastuzumab
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 482
- Registration Number
- NCT00148876
- Locations
- 🇩🇪
Johann Wolfgang Goethe Universität, Universitätsfrauenklinik, Frankfurt / Main, Hessen, Germany
Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00151034
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸California City of Hope National Medical Group, Duarte, California, United States
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00146549
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00146042
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT00140140
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City of Hope Comprehensive Cancer Care Center, Duarte, California, United States
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Duke University
- Target Recruit Count
- 33
- Registration Number
- NCT00134680
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸Siteman Cancer Center, Washington University, St. Louis, Missouri, United States
🇺🇸Lombardi Cancer Institute, Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.